AstraZeneca

News

Radiology technician examens mammography test on location

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer ...

The European Commission has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant treatment for breast cancer, extending its lead over would-be rivals in the PARP inhibitor class

News

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be

News

AstraZeneca raises 2022 guidance, names Demaré as non-exec c...

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – have allowed the company t

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

FDA verdict on Enhertu in HER2-low breast cancer due before ...

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the dr

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

News

Court won't raise Seagen damages award in Enhertu patent dis...

A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu, but declined to raise the sum despite concl

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer ...

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca raises 2022 guidance, names Demaré as non-exec c...

FDA verdict on Enhertu in HER2-low breast cancer due before ...

Roche's fast-growing eye drug Vabysmo set for EU approval

Court won't raise Seagen damages award in Enhertu patent dis...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks